CADL
Income statement / Annual
Last year (2025), Candel Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Candel Therapeutics Inc's net income was -$38.18 M.
See Candel Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$125.00 K |
$125.00 K |
$125.00 K |
$125.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$125.00 K
|
$125.00 K
|
$125.00 K
|
$125.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$30.50 M
|
$19.31 M
|
$24.51 M
|
$20.79 M
|
$15.18 M
|
$8.75 M
|
$6.61 M
|
| General & Administrative Expenses |
$17.77 M
|
$14.06 M
|
$13.89 M
|
$14.06 M
|
$10.67 M
|
$5.18 M
|
$2.56 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.77 M
|
$14.06 M
|
$13.89 M
|
$14.06 M
|
$10.67 M
|
$5.18 M
|
$2.56 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$48.00 K
|
-$1.08 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$48.27 M
|
$33.37 M
|
$38.39 M
|
$34.80 M
|
$24.78 M
|
$13.94 M
|
$9.16 M
|
| Cost And Expenses |
$48.27 M
|
$33.37 M
|
$38.39 M
|
$34.80 M
|
$24.78 M
|
$13.94 M
|
$9.16 M
|
| Interest Income |
$3.92 M
|
$1.09 M
|
$2.08 M
|
$1.22 M
|
$0.00
|
$111.00 K
|
$1.07 M
|
| Interest Expense |
$2.12 M
|
$2.09 M
|
$2.60 M
|
$1.71 M
|
$53.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$845.00 K
|
$990.00 K
|
$960.00 K
|
$778.00 K
|
$232.00 K
|
$91.00 K
|
$43.00 K
|
| EBITDA |
-$35.22 M |
-$52.10 M |
-$34.38 M |
-$16.31 M |
-$24.42 M |
-$13.10 M |
-$8.42 M |
| EBITDA Ratio |
0
|
0
|
0
|
-130.46
|
-195.34
|
-104.76
|
-67.38
|
| Operating Income Ratio |
0
|
0
|
0
|
-277.39
|
-197.2
|
-110.48
|
-72.3
|
| Total Other Income/Expenses Net |
$10.08 M
|
-$21.81 M
|
$452.00 K
|
$15.93 M
|
-$10.40 M
|
-$3.87 M
|
$797.00 K
|
| Income Before Tax |
-$38.18 M
|
-$55.18 M
|
-$37.94 M
|
-$18.79 M
|
-$36.12 M
|
-$17.68 M
|
-$8.24 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-150.35
|
-288.99
|
-141.44
|
-65.92
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$38.18 M
|
-$55.18 M
|
-$37.94 M
|
-$18.79 M
|
-$36.12 M
|
-$17.68 M
|
-$8.24 M
|
| Net Income Ratio |
0
|
0
|
0
|
-150.35
|
-288.99
|
-141.44
|
-65.92
|
| EPS |
-0.72 |
-1.74 |
-1.31 |
-0.0994 |
-1.26 |
-1.18 |
-0.43 |
| EPS Diluted |
-0.72 |
-1.74 |
-1.31 |
-0.0994 |
-1.26 |
-1.18 |
-0.43 |
| Weighted Average Shares Out |
$52.96 M
|
$31.68 M
|
$28.94 M
|
$28.82 M
|
$28.69 M
|
$18.71 M
|
$18.71 M
|
| Weighted Average Shares Out Diluted |
$52.96 M
|
$31.68 M
|
$28.94 M
|
$28.82 M
|
$28.69 M
|
$18.71 M
|
$18.71 M
|
| Link |
|
|
|
|
|
|
|
